// App-Quantinova.ai

82 : Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer.

Researchers

Presenter

  • Jayesh Desai

Principal Investigators

  • Marwan Fakih

  • Katrina Sophia Pedersen

  • Yong Sang Hong

  • Neil Howard Segal

  • Simon Allen

  • Lorna Bailey

  • Christelle Lenain

  • Danny Lu

  • Pakeeza Zahra Sayyed

  • Jochen Schulze

  • Michael Cecchini

Medical Centers

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • City of Hope National Medical Center, Duarte, CA

  • Washington University School of Medicine, St. Louis, MO

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Genentech, Inc., South San Francisico, CA

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Hoffmann-La Roche Ltd, Mississauga, ON, Canada

  • Yale Cancer Center, New Haven, CT

Locations

  • Australia

  • United States

  • Republic of South Korea

  • United Kingdom

  • Switzerland

  • Canada

Companies

  • Genentech, Inc.

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Atezolizumab

  • Oxaliplatin

  • Regorafenib

  • Irinotecan

  • Isatuximab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT03555149

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved